neuroprotection

Toronto, Canada — August 14, 2026 Quantum BioPharma Ltd. reported continued progress on its lead therapeutic program Lucid-MS, following...

Zug, Switzerland & Barcelona, Spain, August 10, 2026 Oculis Holding AG and Accure Therapeutics S.L. have entered into an...

ZUG, Switzerland, Aug. 3, 2026 Oculis announced that the U.S. Food and Drug Administration (FDA) has provided positive pre-Investigational...

ZUG, Switzerland – May 7, 2026 Oculis Holding AG announced that the U.S. Food and Drug Administration (FDA) has...

MIAMI, May 1, 2026 InspireMD, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved its...

Taipei, Taiwan — February 6, 2026 Lumosa Therapeutics has announced positive Phase 2 clinical trial outcomes for LT3001 (odatroltide),...

JACKSON CENTER, Pa., November 3, 2025 — Halberd Corporation, in collaboration with Mississippi State University (MSU), announced continued efforts...

October 14, 2025 | Zug, Switzerland — Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company advancing therapies for...